Meeting
2014 ASCO Annual Meeting
Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes.
Authors
Maren K. Levin
Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX
Maren K. Levin , Kai Wang , Roman Yelensky , Ying Cao , Corinne Ramos , Glenn D. Hoke , John E. Pippen Jr., Joanne Lorraine Blum , Barry Don Brooks , Gary A. Palmer , Norma Alonzo Palma , Sohail Balasubramanian , Jeffrey S. Ross , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 555)
DOI
10.1200/jco.2014.32.15_suppl.555
Abstract #
555
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel
Poster
2019 ASCO Annual Meeting
Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.
First Author: E. Gabriela Chiorean